You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華海藥業(600521.SH)半年度淨利潤升72.77%至5.78億元
格隆匯 08-30 15:07

格隆匯 8 月 30日丨華海藥業(600521.SH)發佈2020年半年度報告,實現營業收入33.06億元,同比增長24.60%;歸屬於上市公司股東的淨利潤5.78億元,同比增長72.77%;歸屬於上市公司股東的扣除非經常性損益的淨利潤5.37億元,同比增長102.89%;基本每股收益0.40元。經營活動產生的現金流量淨額6.29億元,同比增長3.31%。

報告期內,美國市場業務儘管受FDA禁令和新冠疫情影響,仍基本實現年初制定的銷售目標,新增上市產品1個,17個產品在美國市場佔有率排名居前製劑國際業務部完成東南亞等14個市場50多家新客户的接洽,新遞交了越南、柬埔寨、緬甸等市場的註冊申請。日本公司積極推進產品的國內引進業務,並不斷調研和尋找潛在合作伙伴。歐洲公司持續加深與國內以及美國研發團隊的溝通和聯繫,各項目進程有序推進。同時不斷髮揮前沿信息優勢,加快洲市場拓展。

面對全球持續發酵的新冠疫情,銷售團隊整合資源,精耕細作,以CEP復為契機,全面落實三個沙坦(厄貝沙坦、氯沙坦鉀、纈沙坦)銷售戰略,市場份額逐步恢復;持續跟進重點產品項目,不斷深化與現有客户更全面的多元化合作,多舉措實現銷售增長。同時,銷售團隊需進一步解放思想,積極拓展老產品新客户以及新產品業務,實現原料藥銷售裂變發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account